Important Announcement


ChemIDplus is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Ranibizumab [USAN:INN:BAN:JAN]
RN: 347396-82-1


  • A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
  • Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration

Molecular Formula

  • Unspecified

Classification Codes

  • Angiogenesis Inhibitors
  • Angiogenesis Modulating Agents
  • Antineoplastic Agents
  • Growth Inhibitors
  • Growth Substances
  • Immunologic Factors
  • Treatment of Age-Related Macular Degeneration

Names and Synonyms

Name of Substance

  • Ranibizumab
  • Ranibizumab [USAN:INN:BAN:JAN]

MeSH Heading

  • Ranibizumab


  • Lucentis
  • Ranibizumab
  • rhuFab V2
  • UNII-ZL1R02VT79

Systematic Name

  • Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1 chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain

Registry Numbers

CAS Registry Number

  • 347396-82-1


  • ZL1R02VT79

System Generated Number

  • 0347396821